Sandoz Antitrust Claims Nixed In Bayer’s Yasmin IP Suit
Bayer originally brought the suit in April 2008, seeking to block Sandoz and Watson Pharmaceuticals Inc. from marketing a generic version of the oral contraceptive.
Despite winning a judgment of noninfringement in September 2010, Sandoz had pressed ahead with its counterclaims alleging Sherman Act violations by Bayer and accusing the Leverkusen,...
Already a subscriber? Click here to login